# Samuel M. Brown

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/samuel-m-brown/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,090 |
| Field | Sepsis Diagnosis and Treatment |
| h-index | 70 |
| i10-index | 236 |
| Last Known Institution | Intermountain Medical Center |
| OpenAlex ID | https://openalex.org/A5073422869 |
| ORCID iD | https://orcid.org/0000-0003-1206-6261 |
| Works | 592 |

## Researcher papers

- [Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020](https://scholariq.org/papers/symptom-duration-and-risk-factors-for-delayed-return-to-usual-health-among/)
- [Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients](https://scholariq.org/papers/early-remdesivir-to-prevent-progression-to-severe-covid-19-in-outpatients/)
- [Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study](https://scholariq.org/papers/clinical-severity-of-and-effectiveness-of-mrna-vaccines-against-covid-19-from/)
- [Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity](https://scholariq.org/papers/association-between-mrna-vaccination-and-covid-19-hospitalization-and-disease/)
- [Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021](https://scholariq.org/papers/comparative-effectiveness-of-moderna-pfizer-biontech-and-janssen-johnson-and-amp/)
- [Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19](https://scholariq.org/papers/effect-of-hydroxychloroquine-on-clinical-status-at-14-days-in-hospitalized/)
- [Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/tixagevimab-cilgavimab-for-treatment-of-patients-hospitalised-with-covid-19-a/)

## Researcher topics

- [Sepsis Diagnosis and Treatment](https://scholariq.org/topics/sepsis-diagnosis-and-treatment/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Intensive Care Unit Cognitive Disorders](https://scholariq.org/topics/intensive-care-unit-cognitive-disorders/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Family and Patient Care in Intensive Care Units](https://scholariq.org/topics/family-and-patient-care-in-intensive-care-units/)

## Researcher university

- [Intermountain Medical Center](https://scholariq.org/institutions/intermountain-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.